# BSX — Boston Scientific Corporation

## Company & Research Metadata

- **Company:** Boston Scientific Corporation
- **Ticker:** BSX
- **Exchange:** NYSE
- **Sector / Industry:** Health Care / medical devices
- **Template version:** 2.7
- **Research date:** 2026-11-07
- **Valuation / score price snapshot:** $42.75 — 2026-11-06 regular-session close, America/New_York
- **Valuation refresh date:** 2026-11-07
- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Primary operating period reviewed:** Q3 2026
- **Historical period reviewed:** FY2023–FY2025 and Q1–Q3/9M FY2026
- **Latest investor presentation reviewed:** Q3 2026 financial and operational highlights
- **Latest earnings call reviewed:** Q3 2026 full material Q&A
- **Latest post-earnings management commentary reviewed:** SIMPLAAFY trial publication, November 2, 2026

The share price is a dated research reference, not a live portfolio quote. FolioFacts owns live prices, opportunity scores, zones and rankings.

## What's Changed Since Previous Review

**Current Review:** 2026-11-07  
**Previous Review:** 2026-10-28 competitor-Q&A audit; 2026-10-21 substantive model  
**Update Trigger:** Q3 2026 earnings, guidance and approved valuation refresh

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Growth | Q2 organic +7%, FY2026 5–6% guidance | Q3 +1.5%, FY2026 ~3.75%, Q4 −3% to −1% | Lower near-term earnings power |
| EP and WATCHMAN | Slowing but recovery plausible | EP −5%, U.S. EP −8%; WATCHMAN −6%; management anticipates difficult 2027 | Lower sustainable EPS and multiple |
| Cybersecurity | No modeled global disruption | ~300bp Q3 organic revenue hit, ~$0.07 Q3 adjusted EPS hit; Q4 order normalization | Temporary effect distinct from structural competition |
| Financial quality | Strong margins, acquisition leverage | Q3 adjusted gross margin down to 68%, potential Penumbra finance dilution | Less margin visibility |
| Clinical evidence | WATCHMAN recovery uncertain | SIMPLAAFY monotherapy results supportive but adoption unknown | Potential catalyst, not immediate forecast revenue |
| Fair values | $27.90 / $58.37 / $88.97; P/W $58.40; 25/50/25 | $25.45 / $49.33 / $77.76; P/W $45.23; 35/50/15 | P/W fair value −22.5% from fundamentals |
| Quality / confidence | 80.1/A; confidence 55 | 74.4/B; confidence 45 | Weaker moat, growth and execution certainty |

**Thesis: Weakened.** The share-price change is separate from the fundamental estimate reduction. The operating case is a multiyear recovery requiring evidence of EP share stabilization, WATCHMAN referral improvement and disciplined acquisition financing.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $42.75, November 6, 2026 regular-session close |
| Research Rating | **Hold** (dated fundamental judgment) |
| Bear / Base / Bull Fair Value | $25.45 / $49.33 / $77.76 |
| Scenario Probabilities | 35% / 50% / 15% |
| Probability-Weighted Fair Value | **$45.23** |
| Research-date P/W Return / Bear Return | +5.8% / −40.5% |
| Quality Score / Tier | 74.4 / B |
| Risk Level | Medium-High |
| Valuation Confidence | 45 of 100 |
| Tracking / Ownership | Primary Watchlist / Owned |

**Decision rationale:** The cyber outage explains some of the quarterly shortfall, but EP market-share erosion, WATCHMAN referral weakness and delayed launches constrain 2027 organic growth. Just 5.8% modeled expected return at $42.75 does not warrant a new Buy with material downside risk. FolioFacts determines live price-derived opportunity classifications.

## Investment Thesis

Boston Scientific still sells devices used in recurring cardiovascular and minimally invasive procedures, with valuable physician training relationships, regulatory approvals and product franchises. Interventional Cardiology grew 19% in Q3 and Neuromodulation grew 13%, providing real offsets to weakness elsewhere.

The former double-digit growth case has weakened. Q3 organic revenue rose just 1.5%, EP sales fell 5% globally and WATCHMAN fell 6%. Management sees 2027 as a difficult organic growth year even after the cybersecurity disruption fades. The company needs to regain U.S. EP procedure share, improve WATCHMAN referrals, restore margins and bring new products to market before a return to premium earnings growth can be assumed.

The approved base case now assumes $3.85 of sustainable 2029 EPS and a 18× exit P/E, rather than the prior $4.10 and 20×. This recognizes potential recovery in 2028–2029 without assuming a quick rebound.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| Cyber disruption | Q3 estimated $150M lost sales and $0.07 adjusted EPS impact should fade, but that cannot explain persistent EP share loss |
| EP competition | The PFA market remains attractive, yet Medtronic, Abbott and Johnson & Johnson compete for physician workflows and BSX is losing U.S. share |
| WATCHMAN demand | Standalone referral declines and competition create a separate structural risk; SIMPLAAFY is encouraging, not a volume forecast |
| Penumbra and capital allocation | Acquired growth can diversify the company but must be evaluated after financing costs and dilution |
| Launch timetable | 2D ICE planned H2 2027; FARAWAVE Ultra early 2028; FARAFLEX 2029. These timing assumptions carry execution risk |

## Business Overview

Boston Scientific sells devices for minimally invasive procedures. Cardiovascular covers electrophysiology, cardiac rhythm management, WATCHMAN left atrial appendage closure, interventional cardiology and vascular therapy; MedSurg includes Endoscopy, Urology and Neuromodulation. Hospitals, physicians and purchasing networks buy devices based on procedure outcomes, training, workflow, evidence and reimbursement. Consumable procedure demand is recurring, but platform innovation can change physician choices.

| Business | Q3 2026 revenue | Organic growth | Business read-through |
|---|---:|---:|---|
| Endoscopy | $741M | −0.6% | China pricing and supply effects |
| Urology | $661M | −3.1% | Commercial execution and procedure challenges |
| Neuromodulation | $331M | +13.0% | Strong growth offset |
| MedSurg total | $1.733B | +0.7% | Diversified but slower |
| Cardiovascular total | $3.406B | +1.9% | Interventional Cardiology strength offset by EP/WATCHMAN |

### Business Takeaway

Boston Scientific's scale and physician relationships make its products durable, but the value of the franchise depends on retaining procedure share and healthy gross profit in the fastest-changing categories.

## Industry, TAM & Market Share

Aging populations, minimally invasive treatment and better diagnosis expand procedures. Electrophysiology and left-atrial-appendage closure also attract well-financed competitors. Reimbursement changes and clinical evidence can alter adoption quickly. Addressable patient counts must be reduced for eligibility, access and physician willingness to change practice.

### Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Medtronic (MDT) | Direct segments: electrophysiology, cardiac rhythm, neuromodulation | Product scope; no matched operating-scale series | Competes in overlapping procedures | Customer choice in the stated segment only |
| Abbott (ABT) | Direct segments: electrophysiology and structural heart | Product scope; no matched operating-scale series | Competes for physician and hospital adoption | Customer choice in the stated segment only |
| Johnson & Johnson — Biosense Webster | Direct segment: electrophysiology mapping and ablation | Product scope; no matched operating-scale series | EP procedure choice determines overlap | Customer choice in the stated segment only |

### Industry Takeaway

Addressable patient counts must be reduced for eligibility, access and physician willingness to change practice. The base case requires evidence of profitable adoption within that market.

## Customer Economics

Training, clinical evidence and hospital relationships make recurring procedure demand relatively durable. Relevant measures are procedure growth, selling price, device utilization and incremental gross profit, rather than SaaS retention. A growing installed physician base helps only if products maintain outcomes and reimbursement support.

### Customer-Economics Takeaway

The economic test is Cost savings, cash conversion and leverage. A growing installed physician base helps only if products maintain outcomes and reimbursement support.

## Competitive Landscape & Moat

### Competitive Landscape

The comparison is by procedure and device category. Orthopedic exposure alone does not make Stryker a broad Boston Scientific peer.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Medtronic (MDT) | No consistent comparable series | Direct segments: electrophysiology, cardiac rhythm, neuromodulation | Broad clinical distribution and installed devices | Product-level outcomes matter more than group scale | Competes in overlapping procedures |
| Abbott (ABT) | No consistent comparable series | Direct segments: electrophysiology and structural heart | Competing mapping, ablation and Amulet offerings | Diagnostics and nutrition are outside the BSX comparison | Competes for physician and hospital adoption |
| Johnson & Johnson — Biosense Webster | No consistent comparable series | Direct segment: electrophysiology mapping and ablation | Established EP mapping/workflow ecosystem | Does not replicate every BSX cardiovascular franchise | EP procedure choice determines overlap |

### Moat Assessment

Regulatory approvals, clinical data, physician familiarity and broad distribution form a strong moat. Competitive product launches can still shift share. The latest slowdown argues for a stable-to-challenged near-term moat assessment in affected franchises rather than extrapolating historical share gains indefinitely.

**Moat direction:** Weakening — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Regulatory approvals, clinical data, physician familiarity and broad distribution form a strong moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2023 | 14,240 | 12.29% | 69.16% | 16.97% | 1,792 | 12.58% | 233 | 1,464 | 865 | 9,568 |
| FY2024 | 16,747 | 17.61% | 68.41% | 17.93% | 2,645 | 15.79% | 266 | 1,486 | 414 | 11,228 |
| FY2025 | 20,074 | 19.87% | 68.78% | 19.78% | 3,658 | 18.22% | 299 | 1,495 | 1,965 | 11,972 |
| Q1 FY2026 | $5,203 | N/D | 69.5% | 21.2% | $171 (derived: CFO - capex) | 3.3% | $83 | 1,495 | $1,453 | N/D |
| Q2 FY2026 | $5,442 | N/D | 70.7% | 21.6% | $1,279 (derived: current YTD - prior YTD) | 23.5% | $87 (derived: current YTD - prior YTD) | 1,474.8 | $539 | N/D |
| H1 FY2026 | $10,646 | N/D | 70.1% | 21.4% | $1,450 (derived: CFO - capex) | 13.6% | $170 | 1,484.9 | $539 | N/D |
| Q3 FY2026 | $5,138 | N/D | 66.7% | 16.1% | $868 (derived: current YTD - prior YTD) | 16.9% | $72 (derived: current YTD - prior YTD) | 1,452 | $609 | N/D |
| 9M FY2026 | $15,784 | N/D | 69.0% | 19.7% | $2,318 (derived: CFO - capex) | 14.7% | $242 | 1,473.9 | $609 | N/D |

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

Quarterly FCF derivation: Q1 = $348M CFO − $177M capex = $171M; Q2 = ($1,822M − $348M) CFO − ($372M − $177M) capex = $1,279M; Q3 = ($2,870M − $1,822M) CFO − ($552M − $372M) capex = $868M. Quarterly SBC: Q1 $83M, Q2 $170M − $83M = $87M, Q3 $242M − $170M = $72M. Corresponding Q3 SBC/FCF is approximately 8.3% and 9M SBC/FCF approximately 10.4%; FolioFacts derives ratios from matching periods rather than accepting a separate stored field.

### Financial Takeaways

Q3 revenue was $5.138B, up 1.5%; GAAP diluted EPS $0.40 versus $0.51 and adjusted EPS $0.73 versus $0.75, below management's $0.80–$0.82 guidance. Adjusted gross margin fell to 68.0% from 71.0%; adjusted operating margin fell to 26.5% from 28.0%. Cyber costs caused material factory absorption and shipping headwinds, but worsening EP mix, WATCHMAN demand and China pricing create structural risks.

The company estimates the August cyber incident reduced Q3 revenue growth approximately 300 basis points and adjusted EPS $0.07, with another 200–300 basis points of Q4 revenue pressure as restocking unwinds. Management cut FY2026 organic growth guidance to ~3.75% and adjusted EPS to $3.16–$3.18; Q4 organic revenue is expected to decline 1–3%. Free cash flow remains positive, but 9M operating cash flow declined from $3.170B to $2.870B. September 30 cash totaled $609M against $11.953B debt. First-year Penumbra financing and share dilution remain uncertain.

**Financial direction:** Deteriorating in organic growth and margins; strong cash conversion persists.

## Management & Capital Allocation

Management's past product commercialization is valuable, but repeated revisions to EP/WATCHMAN forecasts, a cybersecurity disruption and launch delays reduce near-term execution confidence. It plans more than $500M restructuring savings over three years, with more than half the savings on an exit-rate basis by the end of 2027; savings cannot alone recapture share. Penumbra's closing is expected in early 2027 after regulatory review. Previously guided $0.06–$0.08 first-year adjusted EPS dilution may rise with financing costs. The company completed an accelerated $2B repurchase, but new deal dilution and debt must be considered on a per-share basis.

### Management Takeaway

Look for evidence that updated forecasting, product development, supply resilience and acquisition financing translate into stabilized U.S. EP sales, WATCHMAN referrals, improved margins and sustained per-share cash earnings.

## Valuation

### Current Valuation

| Metric | Value |
|---|---:|
| Price Snapshot | $42.75 — November 6, 2026 regular-session close |
| Shares Outstanding | ~1.449B, October 29 2026 share count |
| Market Capitalization | $61.96B |
| Cash / Total Debt | $0.609B / $11.953B as of September 30, 2026 |
| Enterprise Value | $73.31B |
| Trailing P/E | 18.05× |
| Provider Forward P/E | 13.87× |
| EV / Sales | ~3.48× on latest-12-month revenue (not a cash-flow chart series) |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---:|---:|---|
| BSX — Boston Scientific | Subject company | Public | 13.87× | 3.48× | Cash-generative, challenged EP and WATCHMAN organic growth |
| MDT — Medtronic | Device competitor in specific cardiovascular/neuromodulation procedures; diversified valuation anchor | Public | 16.95× | 3.83× | Broader business mix; not a direct group-wide peer |
| ABT — Abbott | EP and LAAC segments; diversified valuation anchor | Public | 18.84× | N/D | Diagnostics/diabetes complicate consolidated comparison |
| JNJ — Biosense Webster | Direct EP ablation and mapping product competitor | Listed parent | N/D | N/D | No matched product-level multiple; not a comparable consolidated P/E |

**Comparable takeaway:** Same-provider November 6 quote convention for listed valuation anchors. The 18× BSX base exit multiple is an independent judgment about future normalized earnings rather than a mechanical peer average.

### Valuation Scenarios

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---:|---:|---|---:|
| Bear | Sustainable 2029 EPS $2.75; exit P/E 13×; 12% discount over three years; prolonged franchise loss | $25.45 | 35% | Higher probability of persistent competition, financing drag and slow growth | −40.5% |
| Base | Sustainable 2029 EPS $3.85; exit P/E 18×; 12% discount over three years; weak 2027 then recovery | $49.33 | 50% | Diversified cash flows and eventual pipeline commercialization | +15.4% |
| Bull | Sustainable 2029 EPS $4.75; exit P/E 23×; 12% discount over three years; strong pipeline and deal execution | $77.76 | 15% | Multiple product recoveries and improved margins required | +81.9% |
| **Probability-Weighted** | 35% × $25.45 + 50% × $49.33 + 15% × $77.76 | **$45.23** | **100%** | Independent scenario weights | **+5.8%** |

### Valuation Takeaway

- **Primary valuation method:** Present value of sustainable 2029 EPS times exit P/E, discounted at 12% over three years. The EPS estimates are after recurring compensation, potential Penumbra financing and share dilution, not a naive extrapolation of adjusted EPS.
- **Valuation refresh date / changes vs. previous:** 2026-11-07. Bear/Base/Bull changed from $27.90/$58.37/$88.97 to $25.45/$49.33/$77.76; probabilities from 25/50/25 to 35/50/15, yielding P/W $45.23 versus $58.40 (−22.5%). Base sustainable EPS decreased from $4.10 to $3.85 and exit P/E from 20× to 18×; bear and bull multiples reduced to 13× and 23×. The 12% discount rate and three-year horizon are retained after reassessment to preserve consistent treatment of uncertain 2029 earnings. These are analyst assumptions, not issuer guidance or consensus.
- **Cross-check methods:** The issuer's 2026 adjusted EPS midpoint $3.17, positive cash flow, current quoted forward P/E 13.87× and similar-date MDT/ABT valuations. The base $3.85 sustainable EPS requires approximately 10% annual EPS growth in 2028 and 2029 after a difficult 2027.
- **Key valuation dependencies:** U.S. EP share stabilization, WATCHMAN referrals, China pricing, margins after cyber, the product timetable, Penumbra financing and dilution.
- **Valuation confidence / Risk Level:** 45/100 / Medium-High (previously 55/100).
- **Margin-of-safety conclusion:** **Hold** at the November 6 $42.75 reference price, with only +5.8% probability-weighted upside and −40.5% bear downside. Indicative research-date zone boundaries are Strong Buy ≤ $27.99, Buy up to $36.19, and Avoid Chasing above $50.26. FolioFacts alone calculates live zones, Opportunity Score and rank.

## Analyst Questions

Full material Q3 2026 earnings-call Q&A, October 28. Questions and responses are original paraphrases rather than a transcript reproduction. Previous Q2 coverage remains in Git history.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Robbie Marcus / JPMorgan | How much of the weak quarter and the difficult 2027 outlook is attributable to the cybersecurity disruption, and how much reflects underlying market weakness? | CFO Jon Monson estimated a $150 million sales hit and $0.07 EPS hit in Q3. Customer restocking after systems returned should produce another two to three points of revenue pressure and $0.04–$0.05 of EPS pressure in Q4. CEO Mike Mahoney said the larger 2027 issue is continued WATCHMAN market weakness and EP share erosion, even if the cyber effects fade. | The outage does not explain the whole reduction in forward earnings power. |
| Larry Biegelsen / Wells Fargo | Why should sales and earnings accelerate in 2028 despite delayed FARAFLEX development and possible new PFA competition? | Mahoney expects interventional and vascular businesses, together with Penumbra, to grow strongly, with MedSurg closer to mid-single-digit market growth. A new cardiac-rhythm platform, additional EP imaging and ablation launches, and possible WATCHMAN label developments are expected to improve the slower franchises. FARAFLEX remains a 2029 opportunity. | The anticipated 2028 recovery depends on multiple introductions and several markets, not one guaranteed launch. |
| Joanne Wuensch / Citi | What internal changes can bridge earnings to 2028, and what remains before the Penumbra deal can close? | Management described staff and cost restructuring, simpler reporting lines, supply-chain work and back-office changes. It expects more than $500 million of savings over three years and more than half of the savings by the end of 2027 on an exit-rate basis. It also said regulatory discussion had extended Penumbra's anticipated closing into early 2027, without a definitive date. | Cost savings may protect earnings, but acquisition timing and underlying growth remain separate risks. |
| Rick Wise / Stifel | Why should MedSurg grow only in the mid-single digits, rather than return to its former 7%–8% growth rate? | Neuromodulation remains strong. Endoscopy faces Chinese pricing cuts until it laps them late in 2027. Urology has suffered from weak stone-product performance and commercial turnover following the Axonics integration. Recent product clearances and added field staff are expected to improve Urology in 2027, while broader MedSurg acceleration is more likely in 2028. | Even outside EP and WATCHMAN, there are execution issues to resolve. |
| Travis Steed / Bank of America | Do the repeated product delays signal a deeper problem with the pipeline, and what has management changed in its forecasting process? | The CFO acknowledged that management had struggled to forecast the changing EP and WATCHMAN business cycle and described expanded scenario modeling, outside data and process changes. Mahoney acknowledged delays of roughly six months on some large platforms, citing development and regulatory complexity and a reorganization intended to improve launch discipline. | Better forecasts must be demonstrated through results; a stronger process is not yet evidence of a better outcome. |
| Josh Jennings / TD Cowen | Is Boston Scientific's estimated 7% weighted-average market growth rate still credible, and how does management view the U.S. EP market? | Mahoney said the overall market-growth estimate remains around 7%, potentially reaching 7%–8% as new categories and Penumbra are added. He continues to see a healthy EP market even while Boston Scientific loses share. Management expects the company to grow below its weighted market rate in 2027 and move back toward it in 2028. | End-market demand and Boston Scientific's competitive performance must be modeled separately. |
| Marie Thibault / BTIG | Why wouldn't restructuring produce adjusted EPS growth in 2027, even if revenue is weak? | Monson said product mix is the biggest constraint. Lower EP and WATCHMAN sales, combined with more intense pricing pressure in China, are expected to weigh on gross margin. Continued investment in quality and development offsets part of the savings. The company expects EPS growth to remain difficult without a revenue recovery. | Savings are an offset to deterioration, not an independent basis for higher earnings. |
| Pito Chickering / Deutsche Bank | Why is THRIVE running behind schedule, and why is VITALYST focusing initially on cardiogenic shock rather than high-risk PCI? | Chief Medical Officer Ken Stein said THRIVE enrollment has been slower than hoped during integration of the SoniVie team. For VITALYST, management wants to first pursue cardiogenic shock, where it believes the clinical need and potential benefit are compelling, rather than lead with the more debated high-risk PCI application. | The development strategy may be sensible, but launch timing and clinical success remain uncertain. |
| Matthew O'Brien / Piper Sandler | Are the FARAWAVE Ultra and FARAFLEX delays due to technical problems, clinical enrollment or manufacturing, and what can be said about the Penumbra delay? | Joe Fitzgerald attributed Ultra's roughly one-quarter slip primarily to design verification and validation across hardware, software and catheter components, rather than a required clinical trial. FARAFLEX has faced regulatory study approvals and practical startup challenges; management expects enrollment to ramp. Mahoney did not add details beyond Penumbra's expected early-2027 close. | These are different bottlenecks, but together they push the commercial recovery further into the future. |
| Matt Taylor / Jefferies | How has Penumbra's expected growth and its first-year EPS dilution changed since the deal was announced? | Monson said Penumbra remains an attractive growth addition, but the original $0.06–$0.08 estimated first-year adjusted EPS dilution used earlier financing assumptions. Higher interest rates may increase that dilution, and management will give a fuller update after closing. | Acquisition-driven growth needs to be judged after financing costs and dilution, not simply by added revenue. |

### Analyst-Q&A Takeaway

The Q3 call made clear that the cyber incident is not the whole problem. Analysts pressed management on EP and WATCHMAN competition, the 2027 trough, restructuring and Penumbra deal dilution, clinical program delays and recovery timing. Management anticipates more improvement in 2028–2029 but acknowledges weak 2027 organic growth and several milestones still ahead. This shifts valuation probability toward the bear case and lowers the sustainable base-case EPS and exit multiple.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| EP ablation | U.S. EP −8% in Q3, losing share | Stabilization, 2D ICE/Ultra launches on time | Persistent share loss through product upgrades | Moat, base-case growth |
| WATCHMAN | Global −6%; U.S. standalone procedures down high teens | Stronger referrals and implementation of supportive clinical evidence | Deeper market slowdown or competitor share gains | Organic growth, scenario probabilities |
| Cyber normalization | Estimated Q3 300bp growth hit, Q4 200–300bp inventory normalization | Manufacturing and shipping margins rebound | Recurring disruption or permanent loss of orders | Near-term margins |
| Pipeline and innovation | EP imaging/ablation launches targeted 2027–2029 | Timely launch and physician adoption | Further timing slips or limited adoption | 2029 earnings, P/E |
| Cash and Penumbra | $609M cash, $11.953B debt, acquisition pending | Adequate cash flow, acceptable dilution and closing | Higher financing cost or integration trouble | Financial score and confidence |
| China price / MedSurg | Competitive pricing and weaker Urology | Price pressure normalizes, new product-led recovery | Continued ASP erosion and missed growth | Gross margin and multiple |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---:|---:|---:|---|
| Business durability and economics | 86 | 25% | 21.50 | Procedure demand, physician relationships, cash-generative product franchises |
| Moat and competitive position | 76 | 25% | 19.00 | EP share loss and WATCHMAN competition despite approvals and clinical base |
| Growth runway and durability | 63 | 20% | 12.60 | Attractive markets, but projected weak 2027 growth |
| Financial quality and balance sheet | 73 | 15% | 10.95 | Positive FCF offset by acquisition financing and lower margins |
| Management, governance and capital allocation | 69 | 15% | 10.35 | Past execution offset by reduced guidance and delayed launches |
| **Quality Score** | **74.4** | **100%** | **74.40** | Price-independent assessment, previously 80.1 |

- **Quality Tier:** B
- **Speculative override:** None

Live opportunity calculations and ranks are owned by FolioFacts. Prior Opportunity Score and Rank history is preserved below, not updated as a live research field.

#### Opportunity Score (Historical November 3, 2026 Snapshot — Not Current)

This table preserves the previously approved **November 3, 2026 price-only** score as archival evidence, including the Quality Score, probability-weighted upside, downside, confidence and shared rank **from that prior research period**. It does **not** apply the November 7 fundamental assumptions. FolioFacts owns all current opportunity scores, trading zones and ranks.

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 80.1 | 80.1 | 30% | 24.0 |
| Probability-weighted upside | +34.3% | 100.0 | 35% | 35.0 |
| Bear-case downside | -35.9% | 14.1 | 20% | 2.8 |
| Risk / valuation confidence | 55 | 55.0 | 15% | 8.3 |
| **Opportunity Score** |  | **70.1** | **100%** | **70.1** |

- **Opportunity Rank (historical):** #5 of 76 on the November 3, 2026 snapshot.
- **Zone Status (historical):** Buy.
- **Score-change rationale (historical):** Price-only November 3 refresh; this is not the current Q3 research assessment.

<!-- NORMALIZED_SCORECARD_END -->

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $45.58 | Buy | Buy | >$30.69–$46.72 | ≤ $30.69 | > $64.89 | $58.37 | $58.40 | +28.1% | 80.1 | 69.5 / #7 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |
| 2026-11-07 (Q3 fundamental refresh) | $42.75 | Hold | Hold / Watch (research date) | >$27.99–$36.19 | ≤ $27.99 | > $50.26 | $49.33 | $45.23 | +5.8% | 74.4 | FolioFacts only | Approved Q3 earnings refresh; 35/50/15 scenarios and $45.23 P/W; confidence 45, deterioration in EP/WATCHMAN and 2027 outlook; previous history preserved |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [Boston Scientific Q3 2026 earnings release](https://news.bostonscientific.com/2026-10-28-Boston-Scientific-announces-results-for-third-quarter-2026) | Company IR | 2026-10-28 / Q3 2026 | Sales, margins, EPS, organic growth, guidance and franchise results |
| [Q3 2026 investor highlights](https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/FOH/q3-2026-foh.pdf) | Company presentation | Q3 2026 | Segment metrics, clinical and commercial milestones |
| [BSX Q3 2026 SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/bsx-20260930.htm) | SEC filing | Filed 2026-11-02 | Financial statements, cash, debt, SBC, shares, cyber risk |
| [BSX Q2 2026 SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm) | SEC filing | Q2/H1 2026 | Interim cumulative cash flow, Q2 diluted shares and SBC |
| [BSX Q1 2026 SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/bsx-20260331.htm) | SEC filing | Q1 2026 | Quarter CFO, capex, SBC, revenue and balance sheet |
| [Q3 2026 earnings-call transcript](https://stockanalysis.com/stocks/bsx/transcripts/718252-q3-2026/) | Transcript | 2026-10-28 | Full material Q&A and forward-looking management commentary |
| [SIMPLAAFY WATCHMAN trial](https://jamanetwork.com/journals/jama/fullarticle/2856271) | Clinical trial, JAMA | 2026-11-02 | Post-implant medication trial outcomes and limitations |
| [BSX historical annual financials](https://stockanalysis.com/stocks/bsx/financials/income-statement/) | Standardized financial data | FY2023–FY2025 | Annual revenue, margins, share count |
| [BSX annual cash flows](https://stockanalysis.com/stocks/bsx/financials/cash-flow-statement/) | Standardized financial data | FY2023–FY2025 | Annual operating FCF and SBC |
| [BSX November 6 close](https://stockanalysis.com/stocks/bsx/history/) | Market data | 2026-11-06 | Dated share price |
| [BSX valuation statistics](https://stockanalysis.com/stocks/bsx/statistics/) | Market data | 2026-11-06 quote, checked 2026-11-07 | Market cap, EV, P/E and EV/Sales |
| [MDT valuation statistics](https://stockanalysis.com/stocks/mdt/statistics/) | Comparable market data | 2026-11-06 quote | Matched provider/price-date peer multiple |
| [ABT valuation statistics](https://stockanalysis.com/stocks/abt/statistics/) | Comparable market data | 2026-11-06 quote | Matched provider/price-date peer multiple |
| [Boston Scientific announces results for second quarter 2026 - Jul 29, 2026](https://news.bostonscientific.com/2026-07-29-Boston-Scientific-announces-results-for-second-quarter-2026) | Company IR / earnings filing | Q2 2026 | Latest operating results, guidance, products and financial supplement |
| [BSX complete earnings-call transcript](https://stockanalysis.com/stocks/bsx/transcripts/652836-q2-2026/) | Transcript | Q2 2026 | Prepared remarks and all material Q&A exchanges |
| [BSX regular-session historical price](https://stockanalysis.com/stocks/bsx/history/) | Market data | 2026-10-20 close | Common price used in returns, scores and zones |
| [BSX historical income statement](https://stockanalysis.com/stocks/bsx/financials/income-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical income statement; source-native currency and definitions |
| [BSX historical balance sheet](https://stockanalysis.com/stocks/bsx/financials/balance-sheet/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical balance sheet; source-native currency and definitions |
| [BSX historical cash flows](https://stockanalysis.com/stocks/bsx/financials/cash-flow-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical cash flows; source-native currency and definitions |
| [Medtronic plc statistics](https://stockanalysis.com/stocks/mdt/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [Abbott statistics](https://stockanalysis.com/stocks/abt/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [SEC XBRL company facts — BSX](https://data.sec.gov/api/xbrl/companyfacts/CIK0000885725.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |